# EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer

> **NCT07649655** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai EpimAb Biotherapeutics Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Unresectable/Metastatic Colorectal Cancer

## Interventions

- **DRUG:** EMB-01
- **DRUG:** Irinotecan
- **DRUG:** TAS-102
- **DRUG:** mFOLFOX6
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT07649655
- **Lead sponsor:** Shanghai EpimAb Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649655, "EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*